| Biofeedback for Psoriasis (NCT05506644) | Bastyr University | 2022-06-07 |
| Impact of Non-surgical Periodontal Therapy in the Management of Plaque Psoriasis. (NCT05311501) | University of Siena | 2022-05-10 |
| Augmenting Standard-of-care Treatment of Plaque Psoriasis by Neuromodulation (NCT05243303) | Burrell College of Health Sciences | 2022-04-26 |
| Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1% (NCT05461456) | OrchestratePharma GmbH | 2022-04-01 |
| Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study (NCT05185258) | Aarhus University Hospital | 2022-02-16 |
| Dermatologic Research Evaluation and Monitoring of Sleep in Moderate-to-Severe Psoriasis (NCT05102474) | University of California, San Francisco | 2022-02-15 |
| Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP (NCT05215561) | Novartis Pharmaceuticals | 2022-02-14 |
| Clinical Trial of Probiotic Supplementation in Psoriasis Vulgaris (NCT05254249) | Dr. Soetomo General Hospital | 2022-02-07 |
| ATG5 as a Serum Marker of Autophagy in Psoriatic Patient (NCT05279638) | Sohag University | 2022-02-01 |
| A Phase 3 Study of Efficacy and Safety of AK101 in Subjects With Psoriasis (NCT05120297) | Akeso | 2021-11-29 |
| Systemic Treatment of Moderate-to-severe Psoriasis in Adults: Update of the French Guidelines (NCT05144165) | Centre of Evidence of the French Society of Dermatology | 2021-11-08 |
| Pilot Study of Traditional Chinese Medicine (Qing-Re-Liang-Xue Decoction) as Complementary Medicine for Psoriasis Vulgaris of Blood-heat Syndrome. (NCT04994951) | The First Affiliated Hospital of Zhejiang Chinese Medical University | 2021-09-01 |
| Plexin B2 Gene Expression and Polymorphisms in Psoriasis (NCT05184348) | South Valley University | 2021-09-01 |
| Prevalence and Risk Factors asSOciated With CArdiac comorbiDIty in psoriAsis (NCT04950218) | Herlev and Gentofte Hospital | 2021-09-01 |
| Ultraviolet Radiation Forecasting Based Heliotherapy For Psoriasis in Bangkok, Thailand (NCT04740983) | Chulalongkorn University | 2021-03-15 |
| The Role Of Neutrophil Proteases As Global Regulators Of Il-1 Family Cytokine Activity In Skin Disorders (NCT04750161) | St. James's Hospital, Ireland | 2021-03-02 |
| Iontophoresis in Psoriasis (NCT03979664) | Wake Forest University Health Sciences | 2021-03-01 |
| Dose Tapering Study of Adalimumab in Psoriasis (NCT04028713) | University Hospital, Ghent | 2021-02-16 |
| Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab (NCT04533737) | LEO Pharma | 2020-12-17 |
| Blue Light in the Treatment of Inflammatory Skin Diseases (NCT06516783) | Medical University of Lodz | 2020-11-27 |
| Modified Intermittent Fasting in Psoriasis (NCT04418791) | University Hospital, Ghent | 2020-10-17 |
| Predicting Inflammatory Skin Disease Response to IL-23 Blockade (NCT04541329) | University of California, San Francisco | 2020-09-16 |
| Blue Light Phototherapy (NCT04343586) | Northwestern University | 2020-09-01 |
| An Explorative Psoriasis Biomarker Study (NCT04394936) | Centre for Human Drug Research, Netherlands | 2020-09-01 |
| Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis (NCT04340076) | Radboud University Medical Center | 2020-08-20 |
| Liver Fibrosis and Gut Microbiota in Patients With Psoriasis Vulgaris and Rheumatoid Arthritis on Methotrexate (NCT04493762) | The University of Hong Kong | 2020-08-13 |
| Glucose Trnsporter and PEDF in Psoriasis (NCT04242082) | Assiut University | 2020-07-31 |
| Improvement of Psoriasis Patients' Adherence to Topical Drugs (NCT04220554) | Odense University Hospital | 2020-06-19 |
| Therapeutic Drug Monitoring of Ixekizumab in Psoriasis Patients (NCT04083612) | University Hospital, Ghent | 2020-05-04 |
| Therapeutic Drug Monitoring of Risankizumab in Psoriasis Patients (BIOLOPTIM-RIS) (NCT05685940) | University Hospital, Ghent | 2020-04-05 |
| A Pilot Study to Explore the Role of Gut Flora in Psoriasis (NCT04099979) | ProgenaBiome | 2020-03-02 |
| Use of Alternative Therapy in Psoriasis Vulgaris Patients (NCT04207216) | Istanbul Medeniyet University | 2020-01-01 |
| Social Media Use of Psoriasis Vulgaris Patients: Multicenter, Survey Work (NCT04207242) | Istanbul Medeniyet University | 2020-01-01 |
| Effect Narrow-Band UVB Radiations (NCT05647187) | South Valley University | 2020-01-01 |
| Impact of Decision-Framing in Psoriasis (NCT04136314) | University of Southern California | 2019-10-21 |
| Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Psoriasis) (NCT03885089) | Pfizer | 2019-10-21 |
| Discovery of Arthritis in Psoriasis Patients for Early Rheumatological Referral (NCT03816917) | Radboud University Medical Center | 2019-06-01 |
| Oral Chinese Herbal Medicine for Psoriasis Vulgaris With Blood Stasis Syndrome (NCT03942198) | Shanghai Yueyang Integrated Medicine Hospital | 2019-06-01 |
| Oral Chinese Herbal Medicine for Psoriasis Vulgaris With Blood Heat Syndrome (NCT03961230) | Shanghai Yueyang Integrated Medicine Hospital | 2019-06-01 |
| Comparison of Scalp Microbiota of the Psoriasis and Seborrheic Dermatitis Patients (NCT03807453) | Istanbul Medeniyet University | 2019-04-25 |
| Metabolic Syndrome in Psoriasis and Psoriatic Arthritis and Correlation With Serum Omentin and Visfatin Levels (NCT03932110) | Istanbul Medeniyet University | 2019-04-15 |
| Combined Oral Vitamin D and UVB Versus UVB Alone in Treatment of Psoriasis Vulgaris (NCT03874975) | Assiut University | 2019-04-01 |
| Secukinumab Efficacy Without the Initial Loading Dose in Patients With Psoriasis (NCT03828643) | Universita di Verona | 2019-03-20 |
| Analysis of Non-Invasively Collected Microneedle Device Samples From Mild Plaque Psoriasis for Use in Transcriptomics Profiling (NCT03795402) | Janssen Research & Development, LLC | 2019-03-15 |
| Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris (NCT03806790) | LEO Pharma | 2019-01-24 |
| A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream in Adolescent Subjects (NCT03819218) | MC2 Therapeutics | 2018-12-27 |
| Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients (BIOLOPTIM-BRO) (NCT04080635) | University Hospital, Ghent | 2018-12-14 |
| This Trial is a Randomised, Multicentre, Investigator-blind, Vehicle and Comparator-controlled, Parallel-group Trial With the Purpose of Evaluation Efficacy, Safety and Convenience of the MC2-01 Cream (NCT03802344) | MC2 Therapeutics | 2018-12-12 |
| The Safety and Efficacy of a Novel HSP90 Inhibitor (CUDC-305) in the Treatment of Moderate to Severe Psoriasis. (NCT03675542) | Aarhus University Hospital | 2018-11-01 |
| To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis). (NCT03731091) | Glenmark Pharmaceuticals Ltd. India | 2018-10-31 |
| Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis (NCT03669757) | LEO Pharma | 2018-09-27 |
| A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis (NCT03614078) | PRCL Research Inc. | 2018-09-25 |
| Role of Topical Treatments in the Modulation of Skin Microbiome in Psoriatic Skin (NCT03584360) | Centre Hospitalier Universitaire de Nice | 2018-09-24 |
| Immunogenetic Profiling of Goeckerman Therapy in the Treatment of Psoriasis Vulgaris (NCT03662685) | University of California, San Francisco | 2018-08-01 |
| Serum Granulysin Level as a Marker to Detect the Severity of Psoriasis (NCT03469219) | Assiut University | 2018-07-01 |
| Therapeutic Drug Monitoring of Guselkumab in Psoriasis Patients (NCT04080648) | University Hospital, Ghent | 2018-06-27 |
| Body PSOriasis: Long-term Relapse CONTROL (NCT03402828) | LEO Pharma | 2018-06-11 |
| Apremilast Treatment for Pruritus and Quality of Life in Scalp Psoriasis (NCT03553433) | University of Zurich | 2018-06-01 |
| Comparison of Oral Versus Subcutaneous Route of Methotrexate Administration in Moderate to Severe Psoriasis (NCT03408756) | Post Graduate Institute of Medical Education and Research, Chandigarh | 2018-04-01 |
| Therapeutic Drug Monitoring of Secukinumab in Psoriasis Patients. (NCT04080661) | University Hospital, Ghent | 2018-03-22 |
| A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream (NCT03462927) | MC2 Therapeutics | 2018-02-08 |
| Skin Irritation of LEO 90100 Foam (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects (NCT03442244) | LEO Pharma | 2018-01-30 |
| Secukinumab Therapy for the Treatment of Moderate to Severe Plaque Psoriasis With Response Monitoring Using Optical Coherence Tomography (OCT). (NCT03307447) | Narrows Institute for Biomedical Research | 2017-12-19 |
| Formulation and Clinical Evaluation of Ethosomal and Liposomal Preparations of Anthralin in Psoriasis (NCT03348462) | Assiut University | 2017-11-30 |
| Clinical Study to Investigate Psorax35 Supplementation in Patients With Psoriasis (NCT03359577) | Arctic Nutrition AS | 2017-11-21 |
| Psoriatic Inflammation Markers Predictive of Response to Adalimumab (NCT03389984) | Poitiers University Hospital | 2017-11-14 |
| A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis (NCT03331835) | LEO Pharma | 2017-11-03 |
| Safety, Efficacy, and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis Vulgaris (NCT03322137) | Sienna Biopharmaceuticals | 2017-10-10 |
| A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream (NCT03308799) | MC2 Therapeutics | 2017-10-03 |
| Multiple Dose Study With Incremental Dosing to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Doses of LEO 32731 in Healthy Male Japanese Subjects. (NCT03231124) | LEO Pharma | 2017-07-25 |
| LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris (NCT02899962) | LEO Pharma | 2017-02-15 |
| PSOREAL - Managing PSOriasis in the REAL World (NCT02935582) | LEO Pharma | 2017-01-01 |
| A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis (NCT03022617) | University of Alabama at Birmingham | 2017-01-01 |
| Vasoconstriction Trial With LEO 90100 Aerosol Foam (NCT02973776) | LEO Pharma | 2016-12-01 |
| Safety and Efficacy of CD10367 in Psoriasis Vulgaris (NCT03025282) | Galderma R&D | 2016-11-03 |
| Exploratory Evaluation of Biomarkers Associated With Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients (NCT03149900) | Diamant Thaci | 2016-10-01 |
| LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris (NCT02888236) | LEO Pharma | 2016-09-01 |
| A Phase 4 Clinical Study of Brodalumab (NCT04183881) | Kyowa Kirin Co., Ltd. | 2016-07-04 |
| TAB08 in Patients With Psoriasis Vulgaris, Not Adequately Controlled With Current Treatment (NCT02796053) | Theramab LLC | 2016-04-01 |
| Efficacy and Safety of Blue Light (453 nm) Treatment for Mild Psoriasis Vulgaris Over Three Months Compared to Vitamin D. (NCT02735187) | Philips Electronics Nederland BV | 2016-03-01 |
| Safety and Efficacy of Once Daily Topical Treatment With LEO 90100 Aerosol Foam in Adolescent Subjects With Plaque Psoriasis (NCT02387853) | LEO Pharma | 2016-03-01 |
| LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis (NCT02668692) | LEO Pharma | 2016-02-01 |
| Xamiol®Gel in BODY Psoriasis: A One-year Non-interventional Study (NCT02636101) | LEO Pharma | 2016-01-01 |
| Pharmacogenomics Study on Treatment of Psoriasis Vulgaris by Methotrexate (NCT02715947) | Central South University | 2015-12-01 |
| Pharmacogenomics Study on Treatment of Psoriasis Vulgaris by Acitretin Capsules (NCT02715960) | Central South University | 2015-12-01 |
| An Exploratory Trial Investigating the Neurogenic Component in Psoriasis Vulgaris by Use of Botulinum Toxin A (NCT02577185) | LEO Pharma | 2015-11-01 |
| Dermatopharmacokinetic Trial of LEO 80185 Gel (NCT02605057) | LEO Pharma | 2015-11-01 |
| LEO 32731 - A Phase I Study in Healthy Subjects (NCT02514694) | LEO Pharma | 2015-07-01 |
| Tissue Sodium in Patients With Psoriasis (NCT04095130) | Charite University, Berlin, Germany | 2015-07-01 |
| Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-IIb Trial) (NCT03372811) | Psoriasis Research Institute of Guangzhou | 2015-06-11 |
| Safety and Efficacy of UC-MSCs in Patients With Psoriasis Vulgaris (NCT02491658) | Affiliated Hospital to Academy of Military Medical Sciences | 2015-04-01 |
| Patient Insights Following Use of LEO 90100 Aerosol Foam and Daivobet® Gel in Subjects With Psoriasis Vulgaris (NCT02310646) | LEO Pharma | 2015-01-01 |
| Phase 2, Open-label, Study of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-line Therapy (NCT02317627) | Kadmon Corporation, LLC | 2014-12-01 |
| A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis (NCT02193815) | Pfizer | 2014-09-01 |
| LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris (NCT02132936) | LEO Pharma | 2014-06-01 |
| LP0058-1005 - A Open-Label, Four-Way Crossover and Food-Effect Study of LEO 32731 in Healthy Subjects (NCT02126371) | LEO Pharma | 2014-05-01 |
| Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis (NCT02125279) | Galderma R&D | 2014-05-01 |
| A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis Vulgaris (NCT02106195) | Kadmon Corporation, LLC | 2014-04-01 |
| Cardiovascular Risk Evaluation in Psoriasis Treated With Photochemotherapy (NCT02990624) | Cairo University | 2014-04-01 |
| A Phase 3 Clinical Study of KHK 4827 (NCT02052609) | Kyowa Kirin Co., Ltd. | 2014-02-01 |